12 completed, 10 unknown, 4 not yet recruiting, 1 enrolling by invitation. 9 Phase 2, 7 Phase 3, 6 Not applicable, 4 Phase 1, 3 Phase 4.
Follow Proliferative Vitreoretinopathy: new trials by email Literature Review of Proliferative Vitreoretinopathy trials Research Report on Proliferative Vitreoretinopathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy Topotecan - Proliferative Vitreoretinopathy, Proliferative Vitreo-Retinopathy | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 50 | 2026-12-01 | 2026-10-16 |
| Imaging and Predictive Modelling of Proliferative Vitreoretinopathy. Proliferative Vitreoretinopathy | Enrolling by invitation | University College, London | 100 | 2026-10-12 | 2026-07-02 | |
| Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy | Not yet recruiting | University College, London | 50 | 2026-04-27 | 2026-05-06 | |
| Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment Intravitreal topotecan, Retinal detachment surgery - Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy | Phase 2 | Not yet recruiting | Unity Health Toronto | 394 | 2025-03-01 | 2025-03-06 |
| Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment Netarsudil Ophthalmic - Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy | Phase 1 / Phase 2 | Recruiting | Massachusetts Eye and Ear Infirmary | 48 | 2025-01-14 | 2026-10-16 |
| "Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy" Methotrexate - Proliferative Vitreoretinopathy | Phase 1 / Phase 2 | Unknown | University of Health Sciences Lahore | 120 | 2024-03-01 | 2024-03-01 |
| Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial Methotrexate Injection, Methotrexate Infusion, Sham Injection - Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment | Phase 2 | Unknown | Cincinnati Eye Institute, Southwest Ohio | 860 | 2024-03-01 | 2024-09-19 |
| A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud - Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy | Phase 2 / Phase 3 | Unknown | Wills Eye | 80 | 2023-02-06 | 2024-07-30 |
| Air Versus Gas Tamponade in Primary Retinal Detachment Pars plana vitrectomy - Retinal Detachment, Proliferative Vitreoretinopathy | Not applicable | Unknown | Benha University | 40 | 2022-09-26 | 2022-09-30 |
| Internal Limiting Membrane Peeling in Retinal Detachment Surgery Control group, Intervention group - Retinal Detachment, Proliferative Vitreoretinopathy | Not applicable | Not yet recruiting | Central Hospital, Nancy, France | 126 | 2022-09-01 | 2022-09-13 |
| Intravitreal Infliximab for Proliferative Vitreoretinopathy Intravitreal infliximab, Pars plana vitrectomy - Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy | Phase 2 | Completed | Cairo University | 66 | 2021-11-26 | 2024-01-19 |
| Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment Intraoperative infusion of 5-FU (200 µg/ml) and LMWH (5 IU/ml), Placebo - Retinal Detachment, Proliferative Vitreoretinopathy | Not applicable | Completed | Alexandria University | 42 | 2021-10-21 | 2023-12-19 |
| Effects of 0.1% Nepafenac on Vitreous Inflammatory Biomarkers in Rhegmatogenous Retinal Detachment and Proliferative Vitreoretinopathy Nepafenac 0.1% eyedrops, Control (placebo) group - Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment | Phase 4 | Completed | Universitas Indonesia | 61 | 2021-04-28 | 2025-09-09 |
| Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients Methotrexate - Proliferative Vitreoretinopathy | Phase 1 | Withdrawn | Stanford University | 2021-04-01 | 2023-04-20 | |
| Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics ocular surgery - Diabetic Retinopathy, Proliferative Vitreoretinopathy | Not applicable | Unknown | The First Affiliated Hospital with Nanjing Medical University | 80 | 2021-01-15 | 2020-12-23 |
| Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair Intravitreal aflibercept injection, Sham control - Retinal Detachment With Multiple Breaks, Unspecified Eye, Proliferative Vitreoretinopathy | Phase 2 | Unknown | M. Ali Khan, MD | 150 | 2020-10-15 | 2022-05-03 |
| Repeated Methotrexate for Proliferative Vitreoretinopathy Grade C Methotrexate - Proliferative Vitreoretinopathy | Phase 2 / Phase 3 | Unknown | Shahid Beheshti University of Medical Sciences | 74 | 2020-08-01 | 2020-07-22 |
| Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Proliferative Vitreoretinopathy 3D Pars Plana Vitrectomy associated with Extensive Brilliant Blue G-Assisted ILM Peeling Method - Proliferative Vitreoretinopathy | Completed | Centro Oftalmológico Dr Charles | 14 | 2020-07-20 | 2020-07-30 | |
| The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure - Proliferative Vitreoretinopathy | Phase 3 | Completed | Aldeyra Therapeutics, Inc. | 106 | 2019-11-15 | 2025-07-09 |
| Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR) Adrenocorticotropic Hormone - Proliferative Vitreoretinopathy | Early Phase 1 | Completed | Johns Hopkins University | 11 | 2019-08-19 | 2023-08-08 |
Showing 20 of 29. Sign in to see all of them.
Vitreoretinopathy, Proliferative (29) · Retinal Detachment (13) · Diabetic Retinopathy (2) · Epiretinal Membrane (1) · Glaucoma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Pterygium (1) · Retinal Perforations (1) · Retinoschisis (1)
Eye Diseases (29) · Retinal Diseases (29) · Cardiovascular Diseases (2) · Diabetes Complications (2) · Diabetes Mellitus (2) · Diabetic Angiopathies (2) · Endocrine System Diseases (2) · Vascular Diseases (2) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Conjunctival Diseases (1) · Genetic Diseases, Inborn (1) · Heredodegenerative Disorders, Nervous System (1) · Nervous System Diseases (1) · Nervous System Malformations (1)
Methotrexate (4) · Heparin, Low-Molecular-Weight (3) · Fluorouracil (2) · Ophthalmic Solutions (2) · Topotecan (2) · Triamcinolone Acetonide (2) · Adrenocorticotropic Hormone (1) · Antimetabolites (1) · Bevacizumab (1) · Bupivacaine (1) · Colchicine (1) · Control Groups (1) · Dexamethasone (1) · Glycerol (1) · Hypromellose Derivatives (1)
Shahid Beheshti University of Medical Sciences (4) · Massachusetts Eye and Ear Infirmary (2) · University College, London (2) · Wills Eye (2) · Aldeyra Therapeutics, Inc. (1) · Alexandria University (1) · Benha University (1) · Cairo University (1) · Central Hospital, Nancy, France (1) · Centro Oftalmológico Dr Charles (1) · Cincinnati Eye Institute, Southwest Ohio (1) · Emory University (1) · Federal University of São Paulo (1) · Johns Hopkins University (1) · M. Ali Khan, MD (1)
United States (11) · Iran (4) · Egypt (3) · United Kingdom (2) · Argentina (1) · Canada (1) · China (1) · Indonesia (1) · Pakistan (1)
Hamid Ahmadieh, MD (3) · Jason Hsu, MD (2) · Leo Kim, MD, PhD (2) · Ahmad Al-Moujahed, MD, PhD, MPH (1) · Ahmad Z Jamil, FCPS,FRCS (1) · Ahmed A Abdel-Kader, MD, PhD (1) · Ahmed A Abdelshafy, MD (1) · Ahmed M Abdelbaki, MD, PhD (1) · Ahmed M Younes, MD, MSc (1) · Ari Djatikusumo, MD (1) · Ayman G Elnahry, MD, PhD (1) · Darius Moshfeghi, MD (1) · Edward Wood, MD (1) · Hany S Hamza, MD, PhD (1) · Hashem Ghoraba, MD (1)
PMID 29621507, PMID 32408387, PMID 12644944, PMID 16829804, PMID 19107502, PMID 20182404, PMID 29282562, PMID 29299741, PMID 30024983, PMID 30451176, PMID 30451186, PMID 31126280, PMID 31744475, PMID 34336257, PMID 34462712, PMID 38433191, PMID 39572739, PMID 42568743, PMID 7488586